Safety, Radiological and Patient Reported Outcomes of i-FACTOR+ Matrix Bone Graft Device – A Canadian, Multicenter, Post-Market Clinical Investigation (CAPREG)
Dr. Christopher Witiw leads this prospective, non-comparative, open-label study evaluating the safety and outcomes of the i-FACTOR+ Matrix Bone Graft Device in various fusion procedures across multiple Canadian centers. Participants are followed for up to two years, with postoperative assessments at 6 months, 12 months, 1 year, and 2 years to collect patient-reported outcomes and monitor safety. CT imaging at 12 months assesses fusion success.
